InMed Pharmaceuticals Inc. (NASDAQ: INM) has unveiled promising preclinical data for its drug candidate INM-901, demonstrating significant potential in addressing neuroinflammation, a key factor in Alzheimer’s disease progression. The findings reveal that INM-901 effectively reduces pro-inflammatory cytokines and inflammasome markers, such as IL-6, IL-1β, IL-2, KC/Gro, and NLRP3, in ex vivo models. This reduction was observed to be dose-dependent and statistically significant, offering hope for a novel approach to treating neurodegenerative diseases.

What sets INM-901 apart is its mechanism of action, which operates independently of the amyloid beta or tau pathology traditionally targeted in Alzheimer’s research. This suggests a broader applicability in treating neurodegenerative conditions beyond Alzheimer’s. Additionally, the compound, which is orally administered, has shown promising results in improving cognition and behavior in long-term animal studies, further underscoring its therapeutic potential.

InMed Pharmaceuticals is now focused on advancing INM-901 through additional preclinical and Investigational New Drug (IND)-enabling studies, with Alzheimer’s disease as the lead indication. The company’s commitment to addressing diseases with high unmet medical needs is evident in its strategic pipeline development, which includes programs targeting ocular and dermatological indications alongside Alzheimer’s.

The implications of these findings are significant, as they open new avenues for the treatment of Alzheimer’s disease and potentially other neurodegenerative disorders. With the global prevalence of Alzheimer’s expected to rise, the development of effective treatments is more critical than ever. InMed’s progress with INM-901 represents a hopeful step forward in the fight against this debilitating disease.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is InMed Pharmaceuticals Reports Promising Preclinical Results for Alzheimer’s Treatment.